Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

To compare day‐to‐day and within‐day variability in glucose‐lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar‐U300) in type 1 diabetes.

• Publication year

  2017

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2017-04-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12938PMID 28295934PMCID 5485013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin degludec : Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U 300 in type 1 diabetes

  2018cited by this paper
• Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

  2017cited by this paper
• Ultrastructural 3D Visualization of Insulin Degludec Multi-Hexamers Upon Subcutaneous Injection in the Pig

  2016cited by this paper
• Euglycaemic glucose clamp: what it can and cannot do, and how to do it

  2016cited by this paper
• Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

  2016cited by this paper
• Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

  2015cited by this paper
• How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

  2015cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

  2014cited by this paper
• Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice

  2014cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

  2012cited by this paper
• Long-acting formulations of insulins

  2011cited by this paper
• Pharmacokinetics and pharmacodynamics of basal insulins.

  2011cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Nocturnal Blood Glucose Control in Type I Diabetes Mellitus

  1993cited by this paper

• Safety and Effectiveness of Insulin Degludec in Patients With Type 2 Diabetes Mellitus With Chronic Liver Disease.

  2026cites this paper
• Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs

  2025cites this paper
• Can implementing spectrum-of-care approaches in management of canine diabetes mellitus improve dog and owner outcomes?

  2025cites this paper
• Factors Accounting for Pharmacodynamic Variability of Basal Insulin Preparations in Euglycemic Clamp Settings in Healthy Individuals

  2025cites this paper
• International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes

  2025cites this paper
• Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins

  2024cites this paper
• Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

  2024cites this paper
• Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.

  2024cites this paper
• Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study

  2024cites this paper
• Evolution of biosynthetic human insulin and its analogues for diabetes management.

  2024cites this paper
• Эволюция инсулинотерапии: прошлое, настоящее, будущее

  2024cites this paper
• Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)

  2024cites this paper
• Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study

  2024cites this paper
• The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range

  2023cites this paper
• Efficacy and safety of basal insulin Degludec 100 IU/mL versus Glargine 300 IU/mL for type 1 diabetes: the single-center INEOX Randomized Controlled Trial.

  2023cites this paper
• Discharge Planning for People with Inpatient Hyperglycaemia: A Review on Pharmacological Management.

  2023cites this paper
• Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades

  2023cites this paper
• Insulin Therapy in Small Animals, Part 1: General Principles.

  2023cites this paper
• Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)

  2022cites this paper
• Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia

  2022cites this paper
• Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial

  2022cites this paper
• Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)

  2022cites this paper
• New Insulins, Biosimilars, and Insulin Therapy

  2022cites this paper
• Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts.

  2022cites this paper
• One hundred years of insulin: Is it time for smart?

  2022cites this paper
• A simulator with realistic and challenging scenarios for virtual T1D patients undergoing CSII and MDI therapy

  2022cites this paper
• Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

  2022influential citation
• Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies

  2022cites this paper
• Rate of Inpatient Hypoglycemia Following a 1:1 Dose Interchange Between Concentrated Insulin Glargine to Insulin Detemir

  2022cites this paper
• One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

  2022influential citation
• ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes

  2022cites this paper
• Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée

  2021cites this paper
• Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey

  2021cites this paper
• Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

  2021cites this paper
• Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

  2021cites this paper
• The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus – outcomes from cross‐over open-label randomized trial

  2021cites this paper
• Effects of Switching From Degludec to Glargine U300 in Patients With Type 1 Diabetes Having Large Day-to-day Glycemic Variability: a Retrospective Study

  2021cites this paper
• One hundred years of insulin therapy

  2021cites this paper
• Basal insulin analogues in people with diabetes and chronic kidney disease

  2021cites this paper
• Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update

  2021cites this paper
• Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials

  2021cites this paper
• New Horizons: Next-Generation Insulin Analogs: Structural Principles and Clinical Goals.

  2021cites this paper
• Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.

  2020cites this paper
• Recent Advances in Insulin Therapy

  2020cites this paper
• Are newer insulin analogues better for people with Type 1 diabetes?

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel

  2020cites this paper
• Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL-1 and Insulin Degludec 100 units · mL-1 in Type 1 Diabetes.

  2020cites this paper
• Insulin Degludec, Generasi Baru Insulin Analog Kerja Sangat Panjang untuk Terapi Diabetes Melitus Tipe 1

  2020influential citation
• Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary

  2020cites this paper
• Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study

  2020cites this paper
• Treatment of type 1 diabetes complicated by problematic hypoglycemia

  2020cites this paper
• Biosynthetic Human Insulin and Insulin Analogs.

  2020cites this paper
• Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

  2020cites this paper
• Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019

  2020cites this paper
• How conclusive is the CONCLUDE trial?

  2020cites this paper
• Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

  2020cites this paper
• Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs

  2020cites this paper
• InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

  2020cites this paper
• In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes

  2020cites this paper
• Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study

  2020cites this paper
• Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes

  2020cites this paper
• Glargine-300: An updated literature review on randomized controlled trials and real-world studies

  2020cites this paper
• Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study

  2020cites this paper
• Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues

  2020cites this paper
• Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring

  2020cites this paper
• Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study

  2020cites this paper
• Degludek: napjaink ideális bázisinzulinja?

  2019cites this paper
• Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.

  2019cites this paper
• A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes

  2019cites this paper
• Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

  2019influential citation
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

  2019cites this paper
• Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)

  2019cites this paper
• Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)

  2019cites this paper
• Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins

  2019cites this paper
• Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.

  2019cites this paper
• Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports

  2019cites this paper
• Use of Insulin in Outpatient Diabetes Management

  2019cites this paper
• Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care

  2019cites this paper
• Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study

  2019cites this paper
• Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

  2019cites this paper
• [Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»].

  2019cites this paper
• Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study

  2019cites this paper
• An overview of prospective drugs for type 1 and type 2 diabetes.

  2019cites this paper
• Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial

  2019cites this paper
• Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

  2019cites this paper
• Farmakologi klinik obat-obat Diabetes Mellitus Tipe 2.

  2019influential citation
• Thérapeutique des désordres glycémiques

  2019cites this paper
• Going Flat Out for Glycemic Control: The Role of New Basal Insulins in Patient-Centered T2DM Management

  2018cites this paper
• Expert Group Recommendations on Detection and Management of Hypoglycemia in Routine Clinical Practice in Insulin Treated Patients with Diabetes.

  2018cites this paper
• Insulin degludec : Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U 300 in type 1 diabetes

  2018influential citation
• Préparations insuliniques au cours de la dernière décennie.

  2018cites this paper
• Povijest i razvoj inzulinske terapije

  2018cites this paper
• Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.

  2018influential citation
• Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?

  2018cites this paper
• Modelling of glucose-insulin dynamics from low sampled data

  2018cites this paper
• Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL

  2018cites this paper
• Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.

  2018cites this paper